Skip to content

Study · Non-randomized trial · n = 207 · 2009

7 results

Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.

Alvarez XA, Sampedro C, Cacabelos R, Linares C, Aleixandre M, García-Fantini M, Moessler H

The international journal of neuropsychopharmacology17 Jun 2009Cited by 22 (Europe PMC)

PMID19531281 (opens in a new tab)DOI10.1017/s1461145709990101 (opens in a new tab)PepBankPUB-19531281
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In AD patients, Cerebrolysin reduced serum TNF-α versus placebo at week 24 in a dose-related manner.

    In plain wordsIn AD patients, Cerebrolysin lowered serum TNF-α more than placebo in a dose-related manner.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSerum TNF-α at week 24
    Study

    n = 207

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    10, 30 or 60 ml · 12 wkAs given in this study (human).

    Source sentences

    Summary
    At week 24, Cere reduced TNF-α and enhanced dissociable IGF-I with respect to placebo in a dose-related manner.
    1 context sentence
    Summary · context
    Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of the neurotrophic compound Cerebrolysin (Cere: 10, 30 or 60 ml for 12 wk).
  2. 02HumanNon-randomized trialEfficacy outcome

    In AD patients, Cerebrolysin increased dissociable IGF-I versus placebo at week 24 in a dose-related manner.

    In plain wordsIn AD patients, Cerebrolysin increased dissociable IGF-I more than placebo in a dose-related manner.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDissociable IGF-I at week 24
    Study

    n = 207

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Nervous system and cognition
    Studied dose
    10, 30 or 60 ml · 12 wkAs given in this study (human).

    Source sentences

    Summary
    At week 24, Cere reduced TNF-α and enhanced dissociable IGF-I with respect to placebo in a dose-related manner.
    1 context sentence
    Summary · context
    Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of the neurotrophic compound Cerebrolysin (Cere: 10, 30 or 60 ml for 12 wk).
  3. 03HumanNon-randomized trialMechanism

    In AD patients, TNF-α decreased in parallel with behavioural disturbances during Cerebrolysin treatment.

    In plain wordsIn AD patients, lower TNF-α during Cerebrolysin treatment occurred with fewer behavioural disturbances.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTNF-α and behavioural disturbances
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    10, 30 or 60 ml · 12 wkAs given in this study (human).

    Source sentences

    Summary
    TNF-α decreased in parallel with behavioural disturbances.
    1 context sentence
    Summary · context
    Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of the neurotrophic compound Cerebrolysin (Cere: 10, 30 or 60 ml for 12 wk).
  4. 04HumanNon-randomized trialEfficacy outcome

    In AD patients, Cerebrolysin at 60 ml increased total IGF-I.

    In plain wordsIn AD patients, Cerebrolysin at 60 ml increased total IGF-I.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseTotal IGF-I
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Nervous system and cognition
    Studied dose
    60 ml · 12 wkAs given in this study (human).

    Source sentences

    Summary
    Increases in total IGF-I were induced by 60 ml Cere and correlated significantly with improvements in global function, disabilities and behaviour in late-onset AD patients.
    1 context sentence
    Summary · context
    Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of the neurotrophic compound Cerebrolysin (Cere: 10, 30 or 60 ml for 12 wk).
  5. 05HumanNon-randomized trialMechanism

    In late-onset AD patients, total IGF-I increases with Cerebrolysin correlated significantly with improved global function.

    In plain wordsIn late-onset AD patients, higher total IGF-I during Cerebrolysin treatment was linked to improved global function.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseTotal IGF-I association with global function
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Nervous system and cognition
    Studied dose
    60 ml · 12 wkAs given in this study (human).

    Source sentences

    Summary
    Increases in total IGF-I were induced by 60 ml Cere and correlated significantly with improvements in global function, disabilities and behaviour in late-onset AD patients.
    1 context sentence
    Summary · context
    Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of the neurotrophic compound Cerebrolysin (Cere: 10, 30 or 60 ml for 12 wk).
  6. 06HumanNon-randomized trialMechanism

    In late-onset AD patients, total IGF-I increases with Cerebrolysin correlated significantly with improvements in disabilities.

    In plain wordsIn late-onset AD patients, higher total IGF-I during Cerebrolysin treatment was linked to improvements in disabilities.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseTotal IGF-I association with disabilities
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Nervous system and cognition
    Studied dose
    60 ml · 12 wkAs given in this study (human).

    Source sentences

    Summary
    Increases in total IGF-I were induced by 60 ml Cere and correlated significantly with improvements in global function, disabilities and behaviour in late-onset AD patients.
    1 context sentence
    Summary · context
    Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of the neurotrophic compound Cerebrolysin (Cere: 10, 30 or 60 ml for 12 wk).
  7. 07HumanNon-randomized trialMechanism

    In late-onset AD patients, total IGF-I increases with Cerebrolysin correlated significantly with improved behaviour.

    In plain wordsIn late-onset AD patients, higher total IGF-I during Cerebrolysin treatment was linked to improved behaviour.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseTotal IGF-I association with behaviour
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Nervous system and cognition
    Studied dose
    60 ml · 12 wkAs given in this study (human).

    Source sentences

    Summary
    Increases in total IGF-I were induced by 60 ml Cere and correlated significantly with improvements in global function, disabilities and behaviour in late-onset AD patients.
    1 context sentence
    Summary · context
    Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of the neurotrophic compound Cerebrolysin (Cere: 10, 30 or 60 ml for 12 wk).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.